REFERENCES
- Pancoast SJ. Aminoglycoside antibiotics in clinical usage. Med Clin North Am 1988; 72: 581–612.
- Smith CR, Lipsky JJ, Laskin OL, et al. Double-blind comparison of the nephrotoxicity and auditory toxicity of gentamicin and tobramycin. N Engl J Med 1980; 302: 1106–1109.
- Moore RD, Smith CR, Lipsky JJ, Mellits ED, Leitman PS. Risk factors for nephrotoxicity in patients treated with aminoglycosides. Ann Intern Med 1984; 100: 352–357.
- Sawyers CL, Moore RD, Lerner SA, Smith CR. A model for predicting nephrotoxicity in patients treated with amino-glycosides. J Infect Dis 1986; 153: 1062–1068.
- Esienberg JM, Koffer H, Glick HA, et al. What is the cost of nephrotoxicity associated with aminoglycosides? Ann Intern Med 1987; 107: 900–909.
- Editorial. Aminoglycoside toxicity. Lancet 1986; II 670-671.
- Shrimpton SB, Milmoe M, Wilson APR et al. Audit of prescription and assay of aminoglycosides in a UK teaching hospital. J Antimicrob Chemother 1993; 31: 599–606.
- Zaske DE, Sawchuck RJ, Gerding DN, Strate RG. Increased dosage requirements of gentamicin in burn patients. J Trauma 1976; 16: 824–828.
- Zaske DE, Cipolle RJ, Strate RJ. Gentamicin dosage requirements:Wide interpatient variation in 242 Surgery patients with normal renal function. Surgery 1980; 87: 164–169.
- Carr MR, Dick SP, Bordley J, Bertino JS. Gentamicin dosing requirements in patients with acute pancreatitis. Surgery 1988; 103: 533–537.
- Levy J, Smith AL, Koup JR, Williams-Warren J, Ramsey B. Disposition of tobramycin in patients with cystic fibrosis: a controlled study. J Padiatr 1984; 105: 117–124.
- Pancorbo S, Compty C, Hessier J. Comparison of gen-tamicin and tobramycin nephrotoxicity in patients receiving individualized - Pharmacokinetics dosing regimens. Biopharm Drug Dispos 1982; 3: 83–88.
- Humes HD, Weinberg JM, Knauss TC. Clinical and pathophysiologic aspects of aminoglycoside nephrotoxicity. Am J Kidney Dis 1982; 2: 5–29.
- British National Formulary. 5. 1.4. Aminoglycosides. In British National Formulary, no. 23; March. 1992, p.210. British Medical Association and Royal Pharmaceutical Society of Great Britain, London.
- Mann HJ, Fuhs DH, Awang R, Ndemo FA, Cerva FA. Altered aminoglycoside Pharmacokinetics in critically ill patients with sepsis. Clin Pharm 1987; 6: 148–163.
- Noone PT, Parsons MC, Pattison JR, Stack RS, Garfield-Davis D, Hughes K. Experience in monitoring gen-tamicin therapy during treatment of serious Gram-negative sepsis. Br J Med 1974; 1: 477–481.
- Spector R, Park GD, Johnson GF, Vessel ES. Therapeutic drug monitoring. Clin Pharmacol Ther 1988; 43: 345–353.
- McInnes GT. The value of therapeutic drug monitoring to the practicing physicians: an hypothesis in need of testing. Br J Clin Pharmacol 1989; 27: 281–284.
- Cunha BA. Amnoglycosides in urology. Urology 1990; 36: 1–14.
- McCormack JP, Jewesson PJ. A critical evaluation of the “therapeutic range” of aminoglycosides. Clin Infect Dis 1992; 14 (1): 320–339.
- Rotheram EB. Clinical response and peak concentra-tions of aminoglycosides [letter]. J Infect Dis 1988; 157: 159.
- Mc Cormack JP, Schentag JJ. Potential impact of quali-tative susceptibility tests on the design of aminoglycoside dos-ing regimens. Drug Intell Clin Pharm 1987; 21: 187–192.
- Moore RD, Smith CR, Lietman PS. Increased risk of renal dysfunction due to interaction of liver disease and aminoglycosides. Am J Med 1986; 80: 1093–1097.
- Desai TK, Tsang TK. Aminoglycoside nephrotoxicity in obstructive jaundice. Am J Med 1988; 85: 47–50.
- Bertino JS, Booker LA, Franck PA, et al. Incidence and significant risk factors for aminoglycoside-associated nephro-toxicity in patients dosed by using individualized Pharmacokinetic monitoring. J Infect Dis 1993; 167: 173–179.
- EORTC. The International Antimicrobial Therapy Cooperative Group of the European Organisation for Research and Treatment of Cancer. Efficacy and toxicity of single daily doses of amikacin and ceftriaxone versus multiple daily doses of amikacin and ceftazidime for infection in patients with cancer and granulocytopenia. Ann Intern Med 1993; 119: 584–593.
- Prins JM, Buller HR, Kuijper EJ, Tange RA, Speelman P. Once versus thrice daily gentamicin in patients with seri-ous infections. Lancet 1993; 341: 335–339.
- Rodzinski E, Kern WV, Reichle A, Moritz T, Schmeiser T, Gaus W. Once-daily versus thrice daily dosing of netilmicin in combination with beta-lactam antibiotics as empirical therapy. J Antimicrob Chemother 1993; 31: 585–598.
- Parker SE, Davey PG. Practicalities of once-daily aminoglycoside dosing. J Antimicrob Chemother 1993; 31: 4–8.